 |
|
Extended Lymphadenectomy and Vein Resection for Pancreatic Head Cancer
Outcomes and Implications for Therapy
Lorenzo Capussotti, MD;
Paolo Massucco, MD;
Dario Ribero, MD;
Luca Viganò, MD;
Andrea Muratore, MD;
Marco Calgaro, MD
Arch Surg. 2003;138:1316-1322.
Hypothesis An aggressive strategy that includes extended lymphadenectomy and vein resection may improve the results of surgical treatment of pancreatic head cancer.
Design Nonrandomized control trial.
Setting Tertiary care referral center.
Patients The study included 149 consecutive patients undergoing macroscopically curative resection for periampullary adenocarcinoma from January 1, 1988, to December 31, 1998.
Interventions A standard resection was performed in 122 cases; an extended lymphadenectomy in 37. Twenty-four patients underwent venous resection.
Main Outcome Measures Data on surgical mortality, morbidity, and postoperative outcome, pathological findings, and long-term survival were analyzed.
Results In-hospital and 60-day operative mortality was 5.4%. Morbidity was 37.5%. Mortality, morbidity, and postoperative stay were nonsignificantly modified by extended lymphadenectomy or venous resection. Extended resection permitted the identification of a significantly higher percentage of nodal metastases beyond the peripancreatic node groups. In patients undergoing vein resection, a significantly higher rate of positive retroperitoneal margin was found. In the 100 patients with ductal adenocarcinoma, the median overall survival and the 5-year actuarial survival rate were 15 months and 8.4%, respectively. A trend toward a better survival was observed in the first 2 years after operation in the extended resection group compared with the standard resection group. Nodal status was the most powerful predictor of overall survival by multivariate analysis.
Conclusions Extended lymphadenectomy and vein resection did not adversely affect postoperative mortality and morbidity. Patients who required a vein resection were less likely to receive a microscopically curative pancreatectomy. Extended resection permitted better pathological staging and was associated with an early advantage in survival, but long-term survival was possible only in patients with favorable prognostic factors.
From the Unit of Surgical Oncology, Institute for Research and Cure of Cancer, Candiolo, Italy, and Department of Surgery, Ospedale Mauriziano Umberto I, Torino, Italy.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Tumor-Node-Metastasis Staging of Pancreatic Adenocarcinoma
Katz et al.
CA Cancer J Clin 2008;0:CA.2007.0012v1-CA.2007.0012.
ABSTRACT
| FULL TEXT
Significance of Common Hepatic Artery Lymph Node Metastases During Pancreaticoduodenectomy for Pancreatic Head Adenocarcinoma
Cordera et al.
Ann. Surg. Oncol. 2007;14:2330-2336.
ABSTRACT
| FULL TEXT
Extended Resection for Pancreatic Adenocarcinoma
Reddy et al.
The Oncologist 2007;12:654-663.
ABSTRACT
| FULL TEXT
Significance of the Depth of Portal Vein Wall Invasion After Curative Resection for Pancreatic Adenocarcinoma
Fukuda et al.
Arch Surg 2007;142:172-179.
ABSTRACT
| FULL TEXT
Pancreatic Resection for M1 Pancreatic Ductal Adenocarcinoma
Shrikhande et al.
Ann. Surg. Oncol. 2007;14:118-127.
ABSTRACT
| FULL TEXT
Extent of Lymph Node Retrieval and Pancreatic Cancer Survival: Information from a Large US Population Database
Schwarz and Smith
Ann. Surg. Oncol. 2006;13:1189-1200.
ABSTRACT
| FULL TEXT
Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival
Massucco et al.
Ann. Surg. Oncol. 2006;13:1201-1208.
ABSTRACT
| FULL TEXT
Feasibility of a Randomized Trial of Extended Lymphadenectomy for Pancreatic Cancer
Pawlik et al.
Arch Surg 2005;140:584-591.
ABSTRACT
| FULL TEXT
Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry
Carpelan-Holmstrom et al.
Gut 2005;54:385-387.
ABSTRACT
| FULL TEXT
|
